ACRS (Aclaris Therapeutics) Cyclically Adjusted FCF per Share: $-1.75 (As of Mar. 2026)


ACRS Aclaris Therapeutics Inc ACRS
33 GF Score
Price $5.51
GF Value $0.44
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Cyclically Adjusted FCF per Share?

Aclaris Therapeutics ACRS -1.96% 33 Cyclically Adjusted FCF per Share is $-1.75 as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 33/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aclaris Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.141. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.75 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-08), Aclaris Therapeutics's current stock price is $5.51. Aclaris Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1.75. Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Aclaris Therapeutics  (NAS:ACRS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aclaris Therapeutics Cyclically Adjusted FCF per Share Related Terms


Aclaris Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Cyclically Adjusted FCF per Share Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.82 -1.75

Aclaris Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.82 -1.83 -1.77 -1.75 -1.75

ACRS vs RLMD, GYRE, SGP: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


ACRS
33GF Score
Aclaris Therapeutics Inc ACRS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.141/330.2130*330.2130
=-0.141

Current CPI (Mar. 2026) = 330.2130.

Aclaris Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.474 241.018 -0.649
201609 -0.465 241.428 -0.636
201612 -0.348 241.432 -0.476
201703 -0.493 243.801 -0.668
201706 -0.386 244.955 -0.520
201709 -0.485 246.819 -0.649
201712 -0.609 246.524 -0.816
201803 -0.718 249.554 -0.950
201806 -0.717 251.989 -0.940
201809 -0.982 252.439 -1.285
201812 -0.706 251.233 -0.928
201903 -0.766 254.202 -0.995
201906 -0.524 256.143 -0.676
201909 -0.585 256.759 -0.752
201912 -0.499 256.974 -0.641
202003 -0.166 258.115 -0.212
202006 -0.257 257.797 -0.329
202009 -0.291 260.280 -0.369
202012 -0.203 260.474 -0.257
202103 -0.243 264.877 -0.303
202106 -0.226 271.696 -0.275
202109 -0.173 274.310 -0.208
202112 -0.279 278.802 -0.330
202203 -0.344 287.504 -0.395
202206 -0.301 296.311 -0.335
202209 -0.119 296.808 -0.132
202212 -0.288 296.797 -0.320
202303 -0.402 301.836 -0.440
202306 -0.296 305.109 -0.320
202309 -0.348 307.789 -0.373
202312 -0.102 306.746 -0.110
202403 -0.295 312.332 -0.312
202406 -0.173 314.175 -0.182
202409 0.308 315.301 0.323
202412 -0.469 315.605 -0.491
202503 -0.114 319.799 -0.118
202506 -0.082 322.561 -0.084
202509 -0.083 324.800 -0.084
202512 -0.107 324.054 -0.109
202603 -0.141 330.213 -0.141

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.75 mean?
Aclaris Therapeutics (ACRS) has a Cyclically Adjusted FCF per Share of $-1.75 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Cyclically Adjusted FCF per Share too high?
Aclaris Therapeutics' current Cyclically Adjusted FCF per Share is $-1.75. Overall, Aclaris Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Cyclically Adjusted FCF per Share compare to RLMD and GYRE?
Aclaris Therapeutics' Cyclically Adjusted FCF per Share of $-1.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Cyclically Adjusted FCF per Share is $-1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $5.51 — trading 1152.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-1.75. Aclaris Therapeutics' overall GF Score™ is 33/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Cyclically Adjusted FCF per Share is $-1.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.51 is trading 1152.3% above its estimated GF Value™ of $0.44. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Cyclically Adjusted FCF per Share: $-1.75
  • GF Value™: $0.44 vs. price of $5.51 (1152.3% above fair value)
  • GF Score™: 33/100 with 10 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for ACRS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price
$0.44
GF Value